Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{815f932838c7479a967aee7968652e52,
title = "The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer: A nationwide multicenter validation and discovery study",
abstract = "Background and Objectives: The aim was to evaluate the prognostic biomarker potential of the soluble urokinase-type plasminogen activator receptor (suPAR) in plasma samples collected pre- and postoperatively from patients resected for colorectal cancer (CRC). Methods: Patients with CRC were recruited prospectively at six centers from 2006 to 2008. Preoperative plasma samples were available from 494 patients and from 328 of these patients at 6 months postoperatively. Determinations of intact soluble uPAR (suPAR) suPAR(I-III) and the cleaved forms suPAR(I-III) + (II-III) and uPAR(I) were performed. Clinical data were retrieved retrospectively. Results: In a multivariable model based on preoperative plasma samples suPAR(I-III) + (II-III) and uPAR(I) showed an independent statistically significant association to long term survival. When including the change in biomarker level between the pre- and postoperatively samples the hazard ratios were 3.06 (95{\%} confidence interval [CI], 1.78-5.28; P <.0001) and 2.24 (95{\%} CI, 1.59-3.16; P <.0001) for suPAR(I-III) + (II-III) and uPAR(I), respectively. A one-unit decrease in biomarker levels between the pre- and postoperative levels resulted in a 55{\%} and 34{\%} reduction in the risk estimate of death for suPAR(I-III) + (II-III) and uPAR(I), respectively. Conclusion: This study validates previously findings regarding the prognostic significance of suPAR in preoperative samples. The inclusion of postoperative samples added further prognostic information.",
keywords = "biomarkers, colorectal cancer, personalized medicine, Prognosis, Prospective Studies, Biomarkers, Tumor/blood, Humans, Middle Aged, Proportional Hazards Models, Male, Receptors, Urokinase Plasminogen Activator/blood, Denmark/epidemiology, Colorectal Neoplasms/blood, Aged, 80 and over, Adult, Female, Aged, Retrospective Studies",
author = "Rolff, {Hans C} and Christensen, {Ib J} and Svendsen, {Lars B} and Michael Wilhelmsen and Lund, {Ida K} and Tine Thurison and Gunilla H{\o}yer-Hansen and Martin Illemann and Nielsen, {Hans J} and {Danish Collaborative Research Group on Colorectal Cancer}",
note = "{\circledC} 2019 Wiley Periodicals, Inc.",
year = "2019",
month = "12",
doi = "10.1002/jso.25733",
language = "English",
volume = "120",
pages = "1404--1411",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John/Wiley & Sons, Inc. John/Wiley & Sons Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer

T2 - A nationwide multicenter validation and discovery study

AU - Rolff, Hans C

AU - Christensen, Ib J

AU - Svendsen, Lars B

AU - Wilhelmsen, Michael

AU - Lund, Ida K

AU - Thurison, Tine

AU - Høyer-Hansen, Gunilla

AU - Illemann, Martin

AU - Nielsen, Hans J

AU - Danish Collaborative Research Group on Colorectal Cancer

N1 - © 2019 Wiley Periodicals, Inc.

PY - 2019/12

Y1 - 2019/12

N2 - Background and Objectives: The aim was to evaluate the prognostic biomarker potential of the soluble urokinase-type plasminogen activator receptor (suPAR) in plasma samples collected pre- and postoperatively from patients resected for colorectal cancer (CRC). Methods: Patients with CRC were recruited prospectively at six centers from 2006 to 2008. Preoperative plasma samples were available from 494 patients and from 328 of these patients at 6 months postoperatively. Determinations of intact soluble uPAR (suPAR) suPAR(I-III) and the cleaved forms suPAR(I-III) + (II-III) and uPAR(I) were performed. Clinical data were retrieved retrospectively. Results: In a multivariable model based on preoperative plasma samples suPAR(I-III) + (II-III) and uPAR(I) showed an independent statistically significant association to long term survival. When including the change in biomarker level between the pre- and postoperatively samples the hazard ratios were 3.06 (95% confidence interval [CI], 1.78-5.28; P <.0001) and 2.24 (95% CI, 1.59-3.16; P <.0001) for suPAR(I-III) + (II-III) and uPAR(I), respectively. A one-unit decrease in biomarker levels between the pre- and postoperative levels resulted in a 55% and 34% reduction in the risk estimate of death for suPAR(I-III) + (II-III) and uPAR(I), respectively. Conclusion: This study validates previously findings regarding the prognostic significance of suPAR in preoperative samples. The inclusion of postoperative samples added further prognostic information.

AB - Background and Objectives: The aim was to evaluate the prognostic biomarker potential of the soluble urokinase-type plasminogen activator receptor (suPAR) in plasma samples collected pre- and postoperatively from patients resected for colorectal cancer (CRC). Methods: Patients with CRC were recruited prospectively at six centers from 2006 to 2008. Preoperative plasma samples were available from 494 patients and from 328 of these patients at 6 months postoperatively. Determinations of intact soluble uPAR (suPAR) suPAR(I-III) and the cleaved forms suPAR(I-III) + (II-III) and uPAR(I) were performed. Clinical data were retrieved retrospectively. Results: In a multivariable model based on preoperative plasma samples suPAR(I-III) + (II-III) and uPAR(I) showed an independent statistically significant association to long term survival. When including the change in biomarker level between the pre- and postoperatively samples the hazard ratios were 3.06 (95% confidence interval [CI], 1.78-5.28; P <.0001) and 2.24 (95% CI, 1.59-3.16; P <.0001) for suPAR(I-III) + (II-III) and uPAR(I), respectively. A one-unit decrease in biomarker levels between the pre- and postoperative levels resulted in a 55% and 34% reduction in the risk estimate of death for suPAR(I-III) + (II-III) and uPAR(I), respectively. Conclusion: This study validates previously findings regarding the prognostic significance of suPAR in preoperative samples. The inclusion of postoperative samples added further prognostic information.

KW - biomarkers

KW - colorectal cancer

KW - personalized medicine

KW - Prognosis

KW - Prospective Studies

KW - Biomarkers, Tumor/blood

KW - Humans

KW - Middle Aged

KW - Proportional Hazards Models

KW - Male

KW - Receptors, Urokinase Plasminogen Activator/blood

KW - Denmark/epidemiology

KW - Colorectal Neoplasms/blood

KW - Aged, 80 and over

KW - Adult

KW - Female

KW - Aged

KW - Retrospective Studies

UR - http://www.scopus.com/inward/record.url?scp=85074563451&partnerID=8YFLogxK

U2 - 10.1002/jso.25733

DO - 10.1002/jso.25733

M3 - Journal article

VL - 120

SP - 1404

EP - 1411

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 8

ER -

ID: 58214430